Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03239392Phase 1Completed

A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

Role: lead

NCT03239379Phase 1Completed

A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects

Role: lead

NCT03046459Phase 1Completed

A First-in-Human Study of BNZ132-1-40

Role: lead

All 3 trials loaded